Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 15.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,265 shares of the medical equipment provider's stock after selling 612 shares during the period. B. Riley Wealth Advisors Inc.'s holdings in Intuitive Surgical were worth $1,704,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. Brighton Jones LLC increased its position in Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock worth $1,916,000 after purchasing an additional 731 shares in the last quarter. Cornerstone Wealth Management LLC lifted its holdings in Intuitive Surgical by 4.8% in the 4th quarter. Cornerstone Wealth Management LLC now owns 550 shares of the medical equipment provider's stock valued at $287,000 after purchasing an additional 25 shares in the last quarter. Flagship Harbor Advisors LLC boosted its stake in shares of Intuitive Surgical by 3.2% during the 4th quarter. Flagship Harbor Advisors LLC now owns 3,165 shares of the medical equipment provider's stock worth $1,652,000 after purchasing an additional 97 shares during the last quarter. AlphaMark Advisors LLC grew its holdings in shares of Intuitive Surgical by 300.0% during the fourth quarter. AlphaMark Advisors LLC now owns 96 shares of the medical equipment provider's stock worth $50,000 after buying an additional 72 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in shares of Intuitive Surgical by 8.9% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,000 shares of the medical equipment provider's stock valued at $1,044,000 after buying an additional 164 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Citigroup restated a "buy" rating and set a $650.00 target price (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Evercore ISI decreased their price objective on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a report on Wednesday, April 23rd. Royal Bank of Canada lowered their price objective on Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Robert W. Baird reduced their target price on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. Finally, Barclays lowered their price target on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $596.05.

Insider Transactions at Intuitive Surgical

In related news, Director Jami K. Nachtsheim sold 2,400 shares of the firm's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the transaction, the director now directly owns 6,371 shares in the company, valued at $3,312,920. This trade represents a 27.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Robert Desantis sold 188 shares of the business's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $515.91, for a total transaction of $96,991.08. Following the sale, the executive vice president now owns 5,224 shares of the company's stock, valued at approximately $2,695,113.84. The trade was a 3.47% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,111 shares of company stock valued at $15,364,055. Insiders own 0.70% of the company's stock.

Intuitive Surgical Trading Down 0.6%

NASDAQ ISRG traded down $3.41 during mid-day trading on Friday, reaching $552.34. 2,088,630 shares of the company's stock traded hands, compared to its average volume of 1,647,939. Intuitive Surgical, Inc. has a 1-year low of $396.48 and a 1-year high of $616.00. The company has a fifty day simple moving average of $515.81 and a 200-day simple moving average of $538.43. The company has a market cap of $197.97 billion, a price-to-earnings ratio of 86.17, a P/E/G ratio of 5.85 and a beta of 1.70.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The business had revenue of $2.25 billion during the quarter, compared to analyst estimates of $2.19 billion. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. During the same quarter in the previous year, the firm earned $1.50 earnings per share. Equities research analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.